ANDA 202563, held by Hospira Inc. Ceftriaxone Sodium.
As of Nov 15, 2026, ANDA 202563 (Ceftriaxone), held by Hospira Inc, was first approved by FDA on Aug 20, 2012, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2012 | Original application | Approved | None posted |
| CeftriaxoneEQ 1GM BASE/VIAL · injectable;injection | Ceftriaxone Sodium | Discontinued |
| CeftriaxoneEQ 2GM BASE/VIAL · injectable;injection | Ceftriaxone Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
